A Multicenter, Prospective, oBservational Study to assEss the Clinical activitY and Impact on symptOm Burden and patieNts' HRQoL of Treatment With trabecteDin in aSTS in a Real World Setting in Greece — beYOND-STS

Advanced Soft Tissue Sarcoma Clinical Trial

Official title:
A Multicenter, Prospective, oBservational Study to assEss the Clinical activitY and the Impact on symptOm Burden and patieNts' HRQoL of Treatment With trabecteDin in Advanced Soft Tissue Sarcomas in a Real World Setting in Greece. The 'beYOND-STS' Study

Status Completed

Clinical Trial Summary

This non-interventional study aims primarily at assessing the clinical effectiveness and the impact of the therapy on cancer-related symptoms and patients' HRQoL. In addition, it represents an attempt towards gaining experience on the routine use of trabectedin in daily clinical practice in a representative sample of Greek subjects with aSTS.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02618122
Study type	Observational
Source	Genesis Pharma S.A.
Contact
Status	Completed
Phase
Start date	December 2015
Completion date	August 6, 2019

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03670069` - Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas	Phase 1
Terminated	`NCT03698227` - OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients	Phase 2
Active, not recruiting	`NCT03838744` - Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.	Phase 2
Completed	`NCT03009201` - Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery	Phase 1
Not yet recruiting	`NCT06370871` - Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma	Phase 3
Recruiting	`NCT04028063` - Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas	Phase 2
Completed	`NCT01684449` - Gemcitabine Plus Rapamycin Versus Gemcitabine to Treat Advanced Soft Tissue Sarcoma	Phase 1/Phase 2
Recruiting	`NCT06062927` - Geno-radiomics Based Model for Evaluation of Immunotherapy and Targeted Therapy for Advanced Soft Tissue Sarcoma
Completed	`NCT01975519` - A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma	Phase 1/Phase 2
Recruiting	`NCT05333458` - Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom Study	Phase 2
Recruiting	`NCT03138161` - SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma	Phase 1/Phase 2
Active, not recruiting	`NCT03660930` - Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas	Phase 1/Phase 2